Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $28.00

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned a consensus recommendation of “Hold” from the three analysts that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $28.00.

Separately, StockNews.com raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, April 5th.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds have recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in Atara Biotherapeutics in the fourth quarter worth $41,000. SG Americas Securities LLC acquired a new position in shares of Atara Biotherapeutics in the 3rd quarter valued at about $57,000. Harbor Capital Advisors Inc. grew its position in shares of Atara Biotherapeutics by 368.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 164,206 shares during the last quarter. Private Advisor Group LLC raised its stake in Atara Biotherapeutics by 53.0% during the third quarter. Private Advisor Group LLC now owns 95,463 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 33,063 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Atara Biotherapeutics by 29.3% in the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 86,842 shares during the last quarter. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock opened at $0.67 on Thursday. The firm has a market capitalization of $80.68 million, a PE ratio of -0.26 and a beta of 0.70. Atara Biotherapeutics has a one year low of $0.20 and a one year high of $3.02. The stock’s 50 day moving average price is $0.71 and its 200 day moving average price is $0.74.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.05. Atara Biotherapeutics had a negative net margin of 3,220.88% and a negative return on equity of 783.31%. The business had revenue of $4.25 million during the quarter, compared to analyst estimates of $2.45 million. On average, analysts forecast that Atara Biotherapeutics will post -1.3 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.